Emcure Pharmaceuticals profit and loss

Latest FY26

Revenue: ₹9,204cr+16.6% on FY25
EBITDA: ₹1,865cr+26.5% on FY25
Net profit: ₹941cr+33.0% on FY25
EPS: ₹48.77+33.9% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025

Expenses
	9,683	9,204	7,896
	11.0	12.7	67.3
	9,694	9,216	7,963
	1,741	1,693	1,527
	2,402	2,397	1,883
	−215	−433	−264
	1,568	1,552	1,446
	148	144	176
	425	415	384
	2,207	2,130	1,829
	8,277	7,898	6,982
	1,980	1,865	1,474
	1,555	1,450	1,090
Profit
	1,418	1,318	982
	−27.8	−31.3	−10.4
	1,390	1,287	971
	422	393	292
	−50.8	−46.7	−28.3
	371	346	264
	1,019	941	707
	1,019	941	707
	107	166	31.5
	1,126	1,107	739
	1,011	924	681
	7.6	16.9	26.1
Per share
	₹53.35	₹48.77	₹36.43
	₹53.35	₹48.77	₹36.43
Other comprehensive income — detail
	107	166	31.5
	1.7	1.2	−3.6
	0.5	0.3	−1.0
	106	165	34.1
	1,119	1,091	713
	7.6	16.9	25.9
Per share — as-filed variants
	₹53.35	₹48.77	₹36.43
	₹53.35	₹48.77	₹36.43
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	5,755	5,546	4,749
	59.4%	60.3%	60.1%
Adjusted (ex-exceptional items) — derived
	1,418	1,318	982
	−27.8	−31.3	−10.4
	1,039	964	715
	₹54.42	₹49.96	₹36.82

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

EMCURE₹1,775.90

Emcure Pharmaceuticals Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersMANKIND ALKEM TORNTPHARM ERIS GRANULES CONCORDBIO INDGN CAPLIPOINTMcap ₹33,669 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	7,896.0	9,203.5	9,683.5
Other Income	67.3	12.7	11.0
Total Income	7,963.3	9,216.2	9,694.5
Expenses
+ Cost of Materials Consumed	1,526.9	1,692.8	1,741.4
+ Purchases of Stock-in-Trade	1,883.2	2,397.3	2,401.9
+ Changes in Inventories	-263.5	-433.0	-215.1
+ Employee Benefit Expense	1,446.3	1,552.2	1,568.2
+ Finance Costs	175.8	143.7	148.5
+ Depreciation & Amortisation	384.1	415.0	425.1
+ Other Expenses	1,828.7	2,129.7	2,206.8
Total Expenses	6,981.5	7,897.7	8,276.7
EBITDA	1,474.4	1,864.5	1,980.3
EBIT	1,090.3	1,449.5	1,555.2
Profit
PBT before Exceptional Items	981.7	1,318.5	1,417.8
+ Exceptional Items	-10.4	-31.3	-27.8
Pretax Income	971.3	1,287.1	1,389.9
+ Current Tax	292.2	392.6	421.8
+ Deferred Tax	-28.3	-46.7	-50.8
Tax Expense	263.9	345.9	370.9
Net Income	707.5	941.3	1,019.0
+ Net Income — Continuing Ops	707.5	941.3	1,019.0
+ Other Comprehensive Income	31.5	166.1	107.2
Total Comprehensive Income	739.0	1,107.4	1,126.2
Net Income to Common	681.3	924.4	1,011.4
Minority Interest	26.1	16.9	7.6
Per Share
Basic EPS	36.43	48.77	53.35
Diluted EPS	36.43	48.77	53.35
Other Comprehensive Income — detail
+ Other Comprehensive Income	31.5	166.1	107.2
+ Items NOT to be Reclassified to P&L	-3.6	1.2	1.7
+ Tax on Items NOT to be Reclassified	-1.0	0.3	0.5
+ Items to be Reclassified to P&L	34.1	165.3	106.0
Comprehensive Income — Owners of Parent	713.1	1,090.5	1,118.6
Comprehensive Income — Non-controlling Interests	25.9	16.9	7.6
Per Share — as-filed variants
Basic EPS — Continuing Operations	36.43	48.77	53.35
Diluted EPS — Continuing Operations	36.43	48.77	53.35
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	4,749.4	5,546.5	5,755.2
Gross Margin %	60.15	60.26	59.43
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	981.7	1,318.5	1,417.8
− Exceptional Items (reconciliation)	-10.4	-31.3	-27.8
Net Income Adj (tax-effected)	715.0	964.2	1,039.4
EPS Adj	36.82	49.96	54.42
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00
Paid Up Equity Capital	189.5	189.6	189.7

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.